OverviewSuggest Edit

Our mission is to reduce the burden of treatment for patients with ocular diseases through the development of proprietary, injectable products enabling less frequent administration. Our lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD. We are also developing new compounds to treat glaucoma and provide neuroprotection when injected twice per year into the subconjunctiva.

TypePrivate
Founded2011
HQRedwood City, US
Websitegraybug.com

Latest Updates

Employees (est.) (Oct 2019)29(+8%)

GrayBug Office Locations

GrayBug has offices in Redwood City and Baltimore
Redwood City, US (HQ)
275 Shoreline Dr #450
Baltimore, US
6411 Beckley St #200
Show all (2)

GrayBug Financials and Metrics

Summary Metrics

Founding Date

2011

GrayBug total Funding

$128.5 m

GrayBug latest funding size

$80 m

Time since last funding

2 months ago

GrayBug investors

GrayBug's latest funding round in August 2019 was reported to be $80 m. In total, GrayBug has raised $128.5 m
Show all financial metrics

Human Capital Metrics

Embed Graph
Show all human capital metrics

GrayBug Online and Social Media Presence

Embed Graph

GrayBug Blogs

Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration

REDWOOD CITY, Calif., October 2, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal Read more…

Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to Diabetic Macular Edema or Retinal Vein Occlusion

Redwood City, CA – September 18, 2019 –Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal Read more…

Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs

Redwood City, CA – August 20, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), Read more…

GrayBug Frequently Asked Questions

  • When was GrayBug founded?

    GrayBug was founded in 2011.

  • How many employees does GrayBug have?

    GrayBug has 29 employees.

  • Who are GrayBug competitors?

    Competitors of GrayBug include Harbour Antibodies, Rebiotix and PellePharm.

  • Where is GrayBug headquarters?

    GrayBug headquarters is located at 275 Shoreline Dr #450, Redwood City.

  • Where are GrayBug offices?

    GrayBug has offices in Redwood City and Baltimore.

  • How many offices does GrayBug have?

    GrayBug has 2 offices.